Cargando…
Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process
Infliximab (IFX) is an intravenously administered monoclonal antibody antagonizing the effects of tumor necrosis factor-alpha (TNF) systemically and is efficacious in the treatment of inflammatory bowel disease (IBD). However, studies suggest that the anti-inflammatory effects result from local immu...
Autores principales: | Gareb, Bahez, Posthumus, Silke, Beugeling, Max, Koopmans, Pauline, Touw, Daan J., Dijkstra, Gerard, Kosterink, Jos G.W., Frijlink, Henderik W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781063/ https://www.ncbi.nlm.nih.gov/pubmed/31450748 http://dx.doi.org/10.3390/pharmaceutics11090428 |
Ejemplares similares
-
Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
por: Gareb, Bahez, et al.
Publicado: (2020) -
Capsules with Ileocolonic-Targeted Release of Vitamin B(2), B(3), and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process
por: Ahmed, Aisha A., et al.
Publicado: (2023) -
Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets
por: Maurer, Jacoba M., et al.
Publicado: (2015) -
Formulation of a 3D Printed Biopharmaceutical: The Development of an Alkaline Phosphatase Containing Tablet with Ileo-Colonic Release Profile to Treat Ulcerative Colitis
por: Nguyen, Khanh T. T., et al.
Publicado: (2022) -
Formulation and In Vitro Evaluation of Pellets Containing Sulfasalazine and Caffeine to Verify Ileo-Colonic Drug Delivery
por: Broesder, Annemarie, et al.
Publicado: (2021)